When GE announced in November it was spinning off its healthcare business — in which the company will retain a 20% stake — the conglomerate said capital structures, brands and other details were to be determined later. Four months later, analysts appear to be growing impatient with the lack of available information.
At Thursday’s investor day, Barclays analyst Julian Mitchell voiced concerns that the spinoff “is coming up quite soon” and the healthcare unit’s “financial numbers for 2023 that were laid out” by GE “were ex-standup costs.” Mitchell said investors want to know how large those costs will be next year to make sure there’s no “shock” when initial guidance is provided.
